Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis

After 1 year of therapy with the oral thyromimetic, patients with well-compensated NASH cirrhosis had significant improvements in both liver- and heart-related risk factors.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news